Darryl Steensma is counsel in the San Diego office of Latham & Watkins and a member of the firm’s Technology Transactions and Intellectual Property Practices. Dr. Steensma’s practice focuses on representing companies in the biotechnology, pharmaceutical, medical device, and diagnostics industries in a range of intellectual property-based transactions. He advises such clients in matters regarding:
- Complex licensing transactions
- Co-promotion, co-marketing, and co-commercialization agreements
- University license agreements
- Distribution agreements
- Research and collaboration agreements
- Asset purchases and mergers
- Manufacturing and quality agreements
Dr. Steensma also represents various buyers, sellers, investment banks, and other financial institutions in performing business, scientific, and intellectual property due diligence for private and public financings and mergers and acquisitions of life science companies.
Dr. Steensma is registered to practice before the United States Patent and Trademark Office, and provides advice and counsel to clients regarding US and foreign patent prosecution in the biotechnology, pharmaceutical, medical device, and diagnostic industries. He frequently counsels clients regarding current and future patent portfolio strategies. He also represents multinational and start-up companies in pharmaceutical and life sciences litigation, including substantial representation in Hatch-Waxman litigation, and advises clients on regulatory exclusivities and preparing citizen petitions to the FDA. He is admitted to practice before numerous trial and appellate courts including the United States Supreme Court, the Court of Appeals for the Federal Circuit and the Ninth Circuit, the District Courts for the Central and Southern Districts of California, and the California Supreme Court.
Prior to attending law school, Dr. Steensma held postdoctoral research positions at The Scripps Research Institute and at Georgetown University Medical Center. While in law school, he served as a Scientific Advisor to an intellectual property law firm in New York City. He is a named co-inventor on four US patents and is a co-author of over 10 peer-reviewed research publications.
Dr. Steensma is a member of the American Chemical Society, the AIPLA Biotechnology Committee, the BIOCOM Intellectual Property Committee, the San Diego Intellectual Property Law Association, and the Louis M. Welsh Inn of Court.
Dr. Steensma’s recent representative transactions include:
- Amneal Pharmaceuticals in connection with its all-stock merger with Impax Laboratories, creating a company with the 5th largest genetics business in the United States
- Ellipse Technologies in connection with its acquisition by NuVasive for US$380 million
- Fresenius Kabi in connection with its acquisition of the BD Rx pre-filled syringe business
- Ligand in connection with its acquisition of the genetic-engineering company OMT Inc. for US$178 million
- Ignyta in connection with its acquisition of four oncology R&D assets from Cephalon/Teva
- Ignyta in connection with its acquisition of the Taladegib oncology program from Eli Lilly and Co.
- Representation of numerous other clients in connection with strategic agreements and intellectual property transactions, including Apricus Biosciences, CompuVax, Cypress Bioscience, Kalyra Pharmaceuticals, Nestle, Orchid Chemicals & Pharmaceuticals, Prometheus Laboratories, Zavante Therapeutics, and Zogenix
Patent Eligibility of Medical Treatment and Diagnostics, 243rd American Chemical Society National Meeting & Exposition, San Diego
- All there is to know about Abbreviated New Drug Applications (ANDAs), Post-Conference Workshop, 4th Global Polymorphism Symposium, Frankfurt, Germany
- Perspective on Polymorphic Forms in Abbreviated New Drug Applications (ANDAs), 4th Global Polymorphism Symposium, Frankfurt, Germany
- Avoiding Patent Litigation When Exporting Products to the US, Beijing International Pharmaceutical & Chemical Intellectual Property Forum, Beijing, China